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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S3383) weeks post-surgery; or from 4 weeks post-surgery until sacriﬁce at 8
weeks (group 2) (n ¼ 8/antibody/group). At sacriﬁce knees were ﬁxed,
bone changes analysed by mCT, joints then decalciﬁed and OA pathology
scored (average of 2 blinded observers) on serial sagittal sections. SOST
and DKK1 were immunolocalized in 3 mice of each group/antibody.
Results: Treatments were well tolerated with no adverse reactions
observed; all animals completed the study. The signiﬁcant effects of
anti-SOST compared with IgG in operated limbs from the 3 groups are
summarized in Table 1. Increased tibial cortical bone thickness and
subchondral trabecular bone volume were seen by mCT in all groups
with anti-SOST compared with IgG (p<0.05), conﬁrming the efﬁcacy of
the SOST inhibition. However, subchondral bone plate thickness was
only increased by anti-SOST in groups 1 and 2 (p<0.05). Similarly,
histological scoring of subchondral bone sclerosis was only signiﬁcantly
increased with short-term SOST inhibition (groups 1 and 2). Inhibition
of SOST only later in ptOA development (group 2) led to increased
osteophyte size (p<0.05). Importantly, this later anti-SOST treatment
(group 2) also increased articular cartilage structural damage (p<0.05).
Immunohistochemistry revealed that anti-SOST antibody increased the
number of SOST positive cells in calciﬁed cartilage (x24-86%) and sub-
chondral bone (x33-124%) in all groups. While short term SOST inhib-
ition (groups 1 and 2) also increased DKK1 positive cells throughout the
cartilage (x47-180%) and subchondral bone (x250-260%), long-term
SOST blockade (group 3) reduced DKK1 positive cells in all tissues (to
30-60%).
Conclusion: Blocking SOST by systemic administration of a monoclonal
antibody had detrimental effects on the progression of DMM-induced
ptOA in mice. Importantly the effect was dependent on timing, being
more pronounced with short-term administration and particularly
when given later in disease. It is unclear whether the increase in car-
tilage damage (group 2), was a direct effect of anti-SOST on chon-
drocytes, inhibition of synovial SOST, or indirectly through changing
subchondral bone. That long-term SOST-blockade did not alter joint
pathology to the same extent as short-term treatment may be related to
different compensatory changes in other Wnt-regulatory proteins as
seen with DKK1. The temporal difference in SOST blockade in joint
versus distant skeleton may reﬂect when SOST expression in OA is most
pronounced and/or when increases in subchondral bone plate are most
rapid or important in disease progression. The latter may also explain
differences in our ﬁndings compared with those reported in rat ptOA,
where more pronounced and prolonged bone loss occurs. Improved
understanding of the regulation of Wnt signaling in different skeletal
and joint tissues with time, may lead to novel therapeutic approaches in
OA.Table 1
Parameters signiﬁcantly increased in anti-SOST compared to IgG treated mice (+ ¼ p < 0.05, - ¼ no change).
Micro CT Histology score
Cortical Bone Subchondral Trabecular Bone Subchondral Bone Plate Subchondral Bone Plate Osteophyte Size Articular cartilage Erosion
Group 11-4 weeks + + + + - -
Group 24-8 weeks + + + + + +
Group 31-8 weeks + + - - - -591
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Purpose: Excessive mechanical stress loading on articular cartilage is
one of the major factors of osteoarthritis (OA); however, the molecular
mechanisms of cartilage degradation by such loading remain unclear.
The present study therefore analyzed gene expression proﬁles of
articular chondrocytes under mechanical stress loading and inves-
tigated functions of the candidate gene.
Methods: To load mechanical stress on cultured chondrocytes, we used
a programmable cell stretcher system, STB-140 (STREX). Primary
articular chondrocytes from 5-day-old mouse knee joints were seeded
onto stretch chambers at a concentration of 1.0106 cells/chamber.
After 48 h of culture on the chambers, we initially applied a uni-axial
cyclic cell stretch (0.5 Hz, 10% stretch) to the articular chondrocytes for
30 min, then cultured them for an additional 24 h. cDNA microarray(SurePrint G3, Agilent Expression Array) analyses were performed using
samples before and after the mechanical loading. The gene expressions
were conﬁrmed by real-time RT-PCR and immunohistochemistry. The
catabolic ability was assessed by measuring the concentration of
aggrecan released from cultured 3-week-old mouse femoral heads
using the dimethylmethylene blue dye-binding assay. We used mouse
primary articular chondrocytes and mouse chondrogenic cell line
ATDC5 for further in vitro functional analyses.
Results: Microarray analyses revealed that 2,076 genes were increased
more than twice by the mechanical stress loading. Among them, we
focused on Gremlin1, which is one of the most highly expressed genes.
Gremlin1 is known to be a secreted protein that regulates limb devel-
opment as a BMP antagonist during skeletal development, although its
function in articular cartilage is unknown. Immunohistochemistry
revealed that Gremlin1 protein was localized in cytoplasm of mouse
normal knee articular chondrocytes, and the expression was enhanced
in the cells of the experimental mouse OAmodel. In the organ culture of
mouse femoral heads, recombinant human (rh) Gremlin1 treatment
increased aggrecan release into the medium in a dose-dependent
manner. In primary culture of mouse articular chondrocytes, rhGrem-
lin1 treatment induced the expressions of catabolic factors including
Mmp13 and Adamts5, and suppressed those of anabolic factors
including Col2a1, aggrecan and Sox9. Lentiviral overexpression of
Gremlin1 in ATDC5 cells also induced the catabolic factor expressions
and suppressed the anabolic factor expressions. In organ culture of
mouse femoral heads, rhBMP-7 treatment decreased the aggrecan
release, and this anti-catabolic effect was abolished by the co-treatment
of rhGremlin1. To further identify other signals related to the catabolic
effect of Gremlin1 under the mechanical stress, we performed pathway
analyses and gene ontology analyses using the microarray data and
Genespring software, and found the NF-kB signal to be the most potent
candidate pathway associated with both mechanical stress loading and
Gremlin1. To know the involvement of the NF-kB signal with the
catabolic effect by Gremlin1, we used conditional knockoutmice of Rela,
a representative transcription factor of the NF-kB signal. In the organ
culture of femoral heads from Col2a1-Cre;Relaﬂ/ﬂmice, rhGremlin1 did
not induce the aggrecan release, while it normally induced the release
in the control Relaﬂ/ﬂ femoral heads. We further conﬁrmed that sup-
pression of the NF-kB signal by an IKK inhibitor (BMS-345541) treat-
ment also diminished the increase of aggrecan release. Induction of
catabolic factors and suppression of anabolic fators by rhGremlin1 were
also diminished by the IKK inhibitor treatment.
Conclusion: We have identiﬁed Gremlin1 as a catabolic factor induced
by the mechanical stress loaded to articular chondrocytes, not onlythrough the BMP signal but also through the NF-kB signal. Gremlin1
may provide a novel therapeutic target of OA.
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Purpose: In previous studies we found that the down-regulation of the
chemokine MCP5 by TGF-b Type II receptor (TbRII) signaling is required
for joint development. MCP-5 role in arthritis is demonstrated by
human and animal studies. MCP-5, its human homologous MCP-1 and
their sole common receptor CCR2, are increased in the inﬂamed joints
Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489 S339of patients with arthritis and in rodent models of arthritis. We found
that increasing MCP5 expression levels correlate with osteoarthritis
(OA) severity in a murine model of OA (destabilization of medial
meniscus, DMM). By using a Tgfbr2-b-Gal-GFP-BAC mouse, containing
b-gal and GFP reporters for TbRII expression, we have recently charac-
terized the TbRII expressing cells (TbRIIþ) as joint progenitors. Our
previous studies also demonstrated that intra-articular implants of
isolated TbRIIþ cells into DMM knees were able to abolish MCP-5 up-
regulation. Several studies have supported the hypothesis that TGF-b
and PTHrP act in a common signaling cascade to inhibit the develop-
ment of a calcifying phenotype in articular chondrocytes. Our studies
are aimed at determining whether blockade of MCP-5 signaling during
DMM affected OA progression and whether PTHrP could mediate such
signaling.
Methods. We followed two in-vivo approaches: 1) mice subjected to
DMM were treated with an antagonist of the MCP5 receptor CCR2
(RS504393 4mg/Kg/day in drinking water) 1 and 8weeks after DMM; 2)
FACS sorted TbRIIþ cells from Tgfbr2-b-Gal-GFP-BAC limb buds were
injected in the intra-articular space of DMM knees 1 and 8 weeks after
DMM (25X103 cells/15ml PBS) to inhibit MCP-5 expression in articular
cartilage. In both approaches, mice were euthanized 4 and 12-weeks
after DMM. Knees were subjected to micro-CT analysis followed by
decalciﬁcation and parafﬁn embedment for histological studies. Safra-
nin-O/Fast green staining was performed for OA grading following the
OARSI scoring system for mouse. Adjacent sections were subjected to
double-immunoﬂuorescence (IF) studies for TbRII and MCP-5 expres-
sions and in-situ hybridization (ISH) studies for PTHrP mRNA. In our in-
vitro approach, we isolated TbRIIþ cells and cultured them in micro-
mass condition with or without MCP-5 (20 ng/ml) for 3 days. cDNAwas
isolated and subjected to quantitative RT-PCR.
Results. TbRII expression is increased 2 weeks after DMM but its
expression is abolished by 4 weeks after surgery. TbRII decrease is
accompanied by increasing in MCP-5 expression (Fig.1). Inhibition of
MCP5 signaling by both approaches was able to decrease OA lesions
when RS504393 treatment or TbRIIþ cell implantswere performed at an
early stage of OAdevelopment, but not at later stages (Fig. 2). In a parallel
study conducted in our group we found that micro-CT analysis of DMM
posterior medial tibia show an increased mineralization of subchondral
bone compared to sham controls. We found that the subchondral bone
mineralization in the posterior medial tibia induced by DMM was
abolished when mice were treated with RS504393 at early stage com-
pared to untreated (Fig. 3). In our in-vitro approach we demonstrated
that MCP-5 has a direct inhibitory effect on PTHrP expression in TbRIIþ
joint progenitors (Fig.4). Consistently with TbRII expression pattern
during DMM, our in vivo studies show that PTHrP mRNA expression
levels in the periarticular chondrocytes increase at early stage of OA
development (2 week after surgery) but such regular expression is dis-
organized and decreased at later stages after DMM (Fig. 5).
Conclusions. Our ﬁndings show that progression of OA in early stage is
associated with derangement of TbRII-progenitors that leads to an
increase of MCP-5 and suggest that PTHrP might mediate MCP-5 effect
allowing articular chondrocytes to progress toward OA degeneration.
Our results open new perspective for OA treatment.593
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Purpose: Osteoarthritis (OA) is a highly prevalent disease in clinical
practice. It had been reported that various factors such as aging,
trauma and pro-inﬂammatory cytokines are involved in OA patho-
genesis. Oxidative stress is elevated in joint tissues including artic-
ular cartilage in aging and trauma, and it cause activating catabolic
factors such as inﬂammatory cytokines. Antioxidant enzymes such as
Heme oxygenase-1 (HO-1) are an important to prevent an accu-
mulation of oxidative stress, and play an important role in main-
tenance of cellular homeostasis. However, the role of HO-1 in OA
development remain unclear. Bach1 is a transcriptional repressor of
HO-1, thus Bach1-/- mice is upregulated HO-1 in various tissues. The
objective of this study was to deﬁne the function of HO-1 in OA
pathogenesis using Bach1-/- mice by two different animal models of
OA: an aging model, a surgical model.
Methods: To clarify the expression of HO-1 with aging, the knee
joints of newborn, 3, 12 and 22 month-old (m-o) wild-type mice
were assessed by immunohistochemistry using HO-1 antibody
(ab52947). To elucidate whether HO-1 involved in OA patho-
genesis, we used two different animal model of OA; an aging
models and a surgical models. As the aging model, we prepared 22
m-o Bach1-/- mice (n¼16, 22 knees) and wild-type mice (n¼8, 14
knees). Experimental OA was induced in 12 week-old (w-o)
Bach1-/- mice (n¼13) by transection of the medial meniscotibial
ligament and the medial collateral ligament in the right knees and
sacriﬁced 12 weeks later. Wild-type mice (n¼11) were used as a
control. Each knee was stained with Safranin O, and the modiﬁed
OARSI and Mankin’s scoring systems were used to validate the
histological changes of joint tissues. To deﬁne systemic inﬂam-
mation in Bach1-/- mice, the levels of proinﬂammatory cytokines
in serum were measured. Furthermore, to elucidate whether
reduction of OA severity in Bach1-/- mice associated with cellular
homeostasis, we examined LC-3, autophagy marker and the
expression of antioxidases such as SOD2 in knee joints by immu-
nohistochemistry, and also examined the relation between HO-1
and Autophagy or SOD2 in articular chondrocytes using HO-1
siRNA (siHO-1).
Results: The knee joints from wild-type mice at neonatal, 1 to 22
m-o showed an aging-related signiﬁcant reduction in HO-1 positive
cells. Whereas articular cartilage and meniscus in Bach1-/- mice
showed signiﬁcantly more HO-1 positive cells than 22 m-o wild-
type mice. Bach1-/- mice reduced the development of an age-
related OA-like pathology compared with the wild-type mice at 22
m-o. Histological scores indicated that Bach1-/- mice were sig-
niﬁcantly decreased in the severity of the OA-like changes. Bach1
-/- mice inhibited not only degradation of cartilage but also OA-like
changes of other joint tissues such as meniscus degeneration,
osteophyte formation and synovitis. In OA surgical model, Bach -/-
mice reduced the severity of OA-like changes than wild-type mice
as well as an aging model. In aged-mice (22 m-o), proinﬂammatory
cytokines in wild-type mice were signiﬁcantly increased compared
with that in young mice (10 w-o), however, these cytokines in
Bach1-/- mice did not signiﬁcantly change between young- and
aged-mice. In aged-mice, IL-1b, IL-2, IFNg and TNFa in Bach1-/-
mice were signiﬁcantly reduced compared with that in wild-type
mice. The number of LC3-positive chondrocytes in Bach1-/-
mice was signiﬁcantly higher than wild-type mice. SOD2
positive chondrocytes were also higher in Bach1-/- mice than wild-
type mice. Although the expression of SOD2 by siHO-1 was
reduced in Bach1-/- chondrocytes, LC-3 was not directly regulated
by HO-1.
Conclusions: Our present study showed that Bach1 -/- mice reduce the
severity of aging-related and experimental OA-like changes. The acti-
vation of autophagy and the expression of SOD2 were maintained in
articular cartilage of aged-Bach1 -/- mice. Thus, control of HO-1 might
be an effective treatment for OA prevention.
